Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Bambang Adiwijaya"'
Autor:
Tara L Kieffer, Sandra De Meyer, Doug J Bartels, James C Sullivan, Eileen Z Zhang, Ann Tigges, Inge Dierynck, Joan Spanks, Jennifer Dorrian, Min Jiang, Bambang Adiwijaya, Anne Ghys, Maria Beumont, Robert S Kauffman, Nathalie Adda, Ira M Jacobson, Kenneth E Sherman, Stefan Zeuzem, Ann D Kwong, Gaston Picchio
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e34372 (2012)
BackgroundIn patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination with peginterferon and ribavirin (PR) significantly increased sustained virologic response (SVR) rates compared with PR alone. However, genotypic cha
Externí odkaz:
https://doaj.org/article/1dbcfc20320f40f0bb077dc356b2c9f4
Autor:
Kathy D. Miller, István Molnár, Barry A. Siegel, Thomas Wickham, Cynthia X. Ma, Pamela N. Munster, Joseph G. Reynolds, Ian E. Krop, Patricia LoRusso, Anthony F. Shields, Bart S. Hendriks, Victor Moyo, Elena Geretti, Bambang Adiwijaya, Karen Campbell
Publikováno v:
British Journal of Cancer
British journal of cancer, vol 119, iss 9
British journal of cancer, vol 119, iss 9
Background This phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody–liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer. Methods Patients were enrolled in four cohorts: MM-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30ed490d86acd89a47e560cfe096b3ba
http://europepmc.org/articles/PMC6219487
http://europepmc.org/articles/PMC6219487
Autor:
Elena Geretti, Troy Bloom, Victor Moyo, Kurt Miller, Joe Reynolds, Ian E. Krop, Karen Campbell, J Janovsky, Bambang Adiwijaya, Tom Wickham, P Sumner, Cynthia X. Ma, István Molnár, Z Koncki, Christopher W. Espelin, Gabriela Garcia, Nancy Dumont, Patricia LoRusso, Silvia Coma, Pamela N. Munster
Publikováno v:
Cancer Research. 77:P4-21
This abstract was withdrawn by the authors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85105acf59fde7c0b20e895dfbd10b90
https://doi.org/10.1158/1538-7445.sabcs16-p4-21-40
https://doi.org/10.1158/1538-7445.sabcs16-p4-21-40
Autor:
Salvatore Siena, H Hirte, Robert L. Coleman, Eric Pujade-Lauraine, Victor Moyo, Francesco Raspagliesi, Philipp Harter, Joseph Pearlberg, Frédéric Selle, Laurence Gladieff, William Kubasek, R. Wendel Naumann, Felix Hilpert, Bambang Adiwijaya, Kaveh Riahi, Gavin MacBeath, David Cibula, Joyce F. Liu, Isabelle Tabah-Fisch, Isabelle Ray-Coquard, Akos Czibere, Andres Poveda, Rachel Nering, Josep M. del Campo, Ignace Vergote
Publikováno v:
Journal of Clinical Oncology. 34:4345-4353
Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) –mediated ErbB3 signaling and inducing ErbB3 receptor downregulation. This op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3f6818b14e2b51c22835e524b13d5c0
https://doi.org/10.1200/jco.2016.67.1891
https://doi.org/10.1200/jco.2016.67.1891
Autor:
Manuel Modiano, Bambang Adiwijaya, Frances A. Shepherd, Walid S. Kamoun, Enriqueta Felip, Sergio Santillana, Wael A. Harb, Lecia V. Sequist, Maria Q. Baggstrom, M. Cobo, Ariel Lopez-Chavez, Akin Atmaca, Geoffrey Kuesters, Mariano Provencio, Keunchil Park, J. Marc Pipas, Jhanelle E. Gray, Robert C. Doebele, David M. Jackman, Karen Andreas, Byoung Chul Cho
Publikováno v:
The oncologist. 24(8)
BACKGROUND. Seribantumab (MM‐121) is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3/ErbB3) to block heregulin (HRG/NRG)‐mediated ErbB3 signaling and induce receptor downregulation. This open‐
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59a753e0a0aee9847626ec9b72494598
https://pubmed.ncbi.nlm.nih.gov/30975923
https://pubmed.ncbi.nlm.nih.gov/30975923
Autor:
Jonathan Fitzgerald, Gavin MacBeath, Aaron Fulgham, Victor Moyo, Brian Harms, Emily Pace, Art Kudla, Gregory J. Finn, Viara P. Grantcharova, Jeff Kearns, Kristina Masson, Bambang Adiwijaya, Michael D. Curley, Gabriela Garcia, Ulrik B. Nielsen, Birgit Schoeberl, Bill Kubasek, Jaeyeon Kim, Olga Burenkova, Rachel Nering, Marisa Wainszelbaum, Sara Mathews, Ashish Kalra, Defne Yarar, Violette Paragas, Akos Czibere, Kip A. West
Publikováno v:
NPJ Systems Biology and Applications
The ErbB family of receptor tyrosine kinases comprises four members: epidermal growth factor receptor (EGFR/ErbB1), human EGFR 2 (HER2/ErbB2), ErbB3/HER3, and ErbB4/HER4. The first two members of this family, EGFR and HER2, have been implicated in tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b645b897855719c9c27f8b7f814d0d6
https://doi.org/10.1038/npjsba.2016.34
https://doi.org/10.1038/npjsba.2016.34
Autor:
Bambang Adiwijaya, Walid S. Kamoun, Lecia V. Sequist, M. Higgins, Peter A. Kaufman, Sara Ghassemifar, Sergio Santillana, Johannes Ettl, J. Marc Pipas, Joyce F. Liu
Publikováno v:
Journal of Clinical Oncology. 36:2524-2524
2524Background: Seribantumab (MM-121) is an anti-ErbB3 human monoclonal antibody being tested as an anti-cancer therapy for patients with high expression of heregulin mRNA in NSCLC (SHERLOC study, ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73b1c547650479caed3118569acf21af
https://doi.org/10.1200/jco.2018.36.15_suppl.2524
https://doi.org/10.1200/jco.2018.36.15_suppl.2524
Autor:
Angela Brodie, Victor Moyo, Gavin MacBeath, Lucia Wille, Armina A. Kazi, Gauri Sabnis, Bambang Adiwijaya, Gabriela Garcia, Michael D. Curley
Publikováno v:
Molecular cancer therapeutics. 14(11)
Heregulin-driven ERBB3 signaling has been implicated as a mechanism of resistance to cytotoxic and antiendocrine therapies in preclinical breast cancer models. In this study, we evaluated the effects of seribantumab (MM-121), a heregulin-blocking ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abbeab514e8d33d73c500a747b4c3215
https://pubmed.ncbi.nlm.nih.gov/26310543
https://pubmed.ncbi.nlm.nih.gov/26310543
Autor:
Bambang Adiwijaya, Daryl C. Drummond, Jonathan Fitzgerald, Min H. Kang, Hwangeui Cho, Patrick J. Leavey, J. Marc Pipas, William H. Meyer, C. Patrick Reynolds, Paul Harker-Murray
Publikováno v:
Cancer Research. 77:CT146-CT146
Background/Objectives: Children with relapsed or refractory solid tumors have a poor prognosis. Irinotecan is active in some pediatric solid tumors and synergizes with alkylating agents. nal-IRI encapsulates irinotecan into long-circulating, liposome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcdf4c67a302d5732948f361581bc5a4
https://doi.org/10.1158/1538-7445.am2017-ct146
https://doi.org/10.1158/1538-7445.am2017-ct146
Autor:
Sara Mathews, Bambang Adiwijaya, Art Kudla, Akos Czibere, Gavin MacBeath, Jason Baum, Anna Blois, Greg Finn, Mike Cieslewicz, Hong Zhang
Publikováno v:
Clinical Cancer Research. 23:A14-A14
Heregulin (HRG) is the cognate ligand of the human epidermal growth factor receptor 3 (ErbB3) and has been identified as a potent driver of a distinct tumor cell phenotype characterized by enhanced survival that appears to be inherently more resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86a4868e561e6124f4b16a1515aff028
https://doi.org/10.1158/1557-3265.pmccavuln16-a14
https://doi.org/10.1158/1557-3265.pmccavuln16-a14